Anticorps Recombinant de lapin anti-SUMO2/3

SUMO2/3 Recombinant Antibody for IF/ICC, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

IF/ICC, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

241156E1

N° de cat : 84017-5-PBS

Synonymes

SUMO3, SUMO 2, SMT3H1, SMT3A, SMT3 homolog 1



Informations sur le produit

84017-5-PBS cible SUMO2/3 dans les applications de IF/ICC, Indirect ELISA et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène SUMO2/3 Protéine recombinante Ag1135
Nom complet SMT3 suppressor of mif two 3 homolog 3 (S. cerevisiae)
Masse moléculaire calculée 12 kDa
Numéro d’acquisition GenBankBC008420
Symbole du gène SUMO3
Identification du gène (NCBI) 6612
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Protein A purfication
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Ubiquitin is most famous for its function in targeting proteins for degradation by the 26S proteasome, ubiquitin needs to be attached to a substrate in chains (polyubiquitylation) before being recognized by proteasome. Similarly, SUMO (small ubiquitin-related modifier) can be linked to substrates in chains (polysumoylation), SUMO modification has been implicated in many important cellular processes including the control of genome stability, signal transduction, targeting to and formation of nuclear compartments, cell cycle and meiosis. There are 4 confirmed SUMO isoforms in human, SUMO-1, SUMO-2, SUMO-3 and SUMO-4. SUMO-2 and SUMO-3 are nearly identical but are distinct from SUMO-1. SUMO2/3 conjugation was recently widely involved in neuroprotective activities. A substitution (M55V) of SUMO4 was strongly associated with the pathogenesis of type 1 diabetes (T1D) involving NF kappa B related mechanisms.

{{ptg:RelatedPrimaryAntibodies}}